Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
gptkb:dalfampridine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Ampyra
|
| gptkbp:chemicalFormula |
C10H12N4O2
|
| gptkbp:clinicalTrials |
Phase III
symptomatic treatment conducted for efficacy available for healthcare providers follow neurologist recommendations improves walking speed supports_its_use_in_MS |
| gptkbp:commonName |
10 mg twice daily
|
| gptkbp:compatibleWith |
approximately 95%
|
| gptkbp:contraindication |
may include urinary tract infection
seizure_disorders |
| gptkbp:customerFeedback |
generally positive
|
| gptkbp:dosageForm |
extended-release tablet
|
| gptkbp:drugInterdiction |
available from manufacturer
neurological agent well absorbed orally enhances nerve conduction may interact with other CNS agents |
| gptkbp:endOfLife |
5 to 6 hours
|
| gptkbp:formulation |
tablet
|
| gptkbp:hasCapacity |
available through manufacturer programs
|
| gptkbp:hasMuseum |
safety not fully established
|
| gptkbp:hasPopulation |
adults_with_MS
|
| gptkbp:healthcare |
important for efficacy
important for understanding treatment recommended during treatment |
| https://www.w3.org/2000/01/rdf-schema#label |
dalfampridine
|
| gptkbp:impact |
enhance quality of life
improved mobility as prescribed by a physician |
| gptkbp:isATypeOf |
86255-63-0
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
2010
|
| gptkbp:mandates |
improving_walking_in_MS_patients
|
| gptkbp:marketedAs |
gptkb:Acorda_Therapeutics
|
| gptkbp:nutritionalValue |
not extensively metabolized
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:operates_in |
N07XX02
|
| gptkbp:patentType |
for_MS_patients
|
| gptkbp:regulatoryCompliance |
approved in multiple countries
|
| gptkbp:research |
various health organizations
|
| gptkbp:researchFocus |
MS treatment advancements
|
| gptkbp:researchInterest |
ongoing
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
dizziness
headache nausea insomnia |
| gptkbp:supportRole |
monitoring treatment effectiveness
|
| gptkbp:triggerType |
potassium channel blocker
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:waterManagement |
urine
|